2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...
1don MSN
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!
Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...
Kissei Pharmaceutical Co. Ltd. (4547.TO) Japan Half-Year Ended September 30 GROUP 2025 2024 Revenue Y45.83 bln Y42.47 bln Operating Profit (Y6.84 bln) Y1.78 bln Pretax Profit (Y5.62 bln) Y2.24 bln Net ...
Mochida Pharmaceutical Co. Ltd. (4534.TO) Japan Half-Year Ended September 30 GROUP 2025 2024 Revenue Y54.99 bln Y51.10 bln Operating Profit Y4.97 bln Y3.79 bln Pretax Profit Y5.18 bln Y4.08 bln Net ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Stocks to Buy with Exponential Growth Heading into 2026.
Acadia Pharmaceuticals CEO Catherine Owen Adams breaks down the company’s recent rebrand, its expansion into rare disease marketing and how it’s using AI.
Virginia will be home to a workforce training center preparing thousands of people each year for a career in the pharmaceutical industry.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback